Table 2.
T-scores of cognitive domains tested in patients treated with placebo vs exenatide at baseline and 12 weeks. Results expressed as mean (SD). SD, standard deviation.
| Cognitive domain | All baseline Mean (SD) n = 15 | Exenatide Mean (SD) n = 7 | Placebo Mean (SD) n = 8 | ||
|---|---|---|---|---|---|
| Baseline | 12-weeks | Baseline | 12-weeks | ||
| Crystal Intelligence | 51.3 (10.8) | 53.1 (7.2) | 55.6 (12.8) | 49.6 (13.6) | 56.1 (9.7) |
| Auditory Language | 47.8 (10.4) | 46.4 (11.9) | 50.3 (12.5) | 49.4 (9.1) | 48.7 (11.5) |
| Oral Language | 54.8 (14.1) | 53.3 (16.6) | 60.6 (14.2) | 56.6 (11.6) | 61.6 (14.3) |
| Fluid Intelligence | 37.2 (9.9) | 38.4 (8.2) | 52.9 (6.6) | 36.1 (11.6) | 48.3 (12.7) |
| Attention & Executive Function | 33.9 (7.1) | 32.9 (5.2) | 38.1 (9.8) | 34.9 (8.7) | 38.5 (10.8) |
| Executive Function | 38.1 (14.6) | 36.0 (17.0) | 45.0 (12.0) | 39.9 (13.1) | 46.4 (15.4) |
| Processing Speed | 45.7 (10.9) | 43.7 (9.4) | 58.4 (10.4) | 47.5 (12.4) | 59.3 (9.8) |
| Working Memory | 43.9 (12.0) | 48.1 (11.4) | 56.9 (9.1) | 40.3 (11.9) | 49.3 (9.1) |
| Episodic Memory | 46.7 (6.8) | 49.4 (5.3) | 62.1 (13.2) | 44.4 (7.4) | 50.9 (15.2) |